Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 10—October 2019
CME ACTIVITY - Synopsis

Case Studies and Literature Review of Pneumococcal Septic Arthritis in Adults

Amandine Dernoncourt1Comments to Author , Youssef El Samad, Jean Schmidt, Jean Philippe Emond, Charlotte Gouraud, Anne Brocard, Mohamed El Hamri, Claire Plassart, Florence Rousseau, Valéry Salle, Momar Diouf, Emmanuelle Varon, and Farida Hamdad1
Author affiliations: Amiens-Picardie University Medical Center, Amiens, France (A. Dernoncourt, Y. El Samad, J. Schmidt, J.P. Emond, A. Brocard, M. El Hamri, C. Plassart, F. Rousseau, V. Salle, M. Diouf, F. Hamdad); Compiègne Hospital, Compiègne, France (J.P. Emond, C. Gouraud); Senlis Hospital, Senlis, France (A. Brocard); Laon Hospital, Laon, France (M. El Hamri); Beauvais Hospital, Beauvais, France (C. Plassart); Intercommunal Hospital of Creteil, Paris, France (E. Varon)

Main Article

Table 3

Laboratory findings, joint analysis, antimicrobial susceptibility, and serotypes of Pneumococcus-positive cultures for 16 patients with pneumococcal septic arthritis, Picardie region, France, 2005–2016*

Patient age, y/sex Laboratory findings
 Joint analysis
 MIC, mg/L
 Serotype
CRP† Leuk‡ PCT§ Bact Ag U Characteristics Gram stain Culture PEN AMOX CEF
90/M 100 10,400 0.14 Y + Inflammation – + 2 2 0.5 19F
93/F 505 11,900 5.6 Y + Purulent + + 0.016 0.016 0.016 3
34/M 290 14,000 0.36 N NA Purulent + + 0.016 0.016 0.016 10A
68/M 28 78,000 NA Y NA Purulent + + 0.5 0.25 0.25 1
75/M 360 13,800 NA Y NA Purulent + + 0.064 0.016 0.016 NA
42/F 203 44,000 13 Y NA Inflammation – + 0.016 0.016 0.016 23B¶
80/F 385 18,200 NA Y NA Purulent + + 0.016 0.016 0.032 23B¶
61/F 552 6,020 155 Y NA Purulent + + 0.5 0.5 1 1
57/F 391 11,310 NA N NA Inflammation NA + 0.008 0.016 0.016 23B¶
82/F NA 12,200 NA N NA Inflammation + + 0.016 0.016 0.032 6A#
90/F NA NA NA Y + Purulent + – 1 0.5 4 19F
53/F 110 12,800 69.9 Y – NA NA NA 0.016 0.016 0.016 24F¶
69/M 552 8,740 NA Y NA Purulent + + 0.016 0.016 0.016 9N
82/F 178 19,480 3.72 Y NA Purulent + + 0.016 0.016 0.016 8
57/M 450 15,550 NA N NA Purulent – + 0.032 0.016 0.016 23B¶
82/M 240 21,000 0.96 N + Inflammation + + 0.016 0.016 0.016 23B¶

*Ag U, pneumococcal antigen in urine; AMOX, amoxicillin; Bact, bacteremia; CEF, ceftriaxone; CRP, C-protein reactive; leuk, leukyocytes; NA, not available; PCT, procalcitonin; PEN, penicillin; PCV13, pneumococcal 13-valent conjugate vaccine; PPV23, pneumococcal 23-valent polysaccharide vaccine; +, positive; –, negative.
†In mg/L.
‡In cells/mm3.
§In ng/mL.
¶Serotypes not covered by PCV13 or PPV23.
#Serotype covered by PCV13 but not by PPV23.

Main Article

1These authors contributed equally to this article.

Page created: September 12, 2019
Page updated: September 12, 2019
Page reviewed: September 12, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external